Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Wearables like smartwatches can capture a lot of health-related information. Researchers plan to assess the value of tracking…
A podcast for physicians, moderated by CSL Behring’s Bill Maltas, discussed the recommendations for diagnosing and treating t…
What’s it like when Dad has a chronic condition? This Father’s Day, we share three patient experiences with fatherhood.
Without the insulating sheath called myelin, the nervous system would cease to function. Learn about myelin and the lightning…
The March 15-17 event offers a hybrid learning opportunity for doctors and other health care providers who want a deep dive i…
Arthur is stepping forward for those also living with chronic inflammatory demyelinating polyneuropathy (CIDP).
In USA TODAY: When a 12-year-old experienced numbing inflammation, then paralysis, a plasma-based medicine was the answer.
Different than an IV, this method delivers medicine below the skin and can be self-administered by some patients.
Learn more about this commonly misdiagnosed disease associated with weakness, numbness and tingling in the arms and legs.
In nine years of managing her CIDP, Rosemarie acknowledges limits but also treasures her energy.
Caroline, a CIDP patient, created a canvas of light and hope to capture the treatment phase.
An end to confusion: CIDP patient Darryl paints the relief of diagnosis.
Americas
Asia Pacific
Middle East
Europe